SteelPeak Wealth LLC Buys New Shares in Twist Bioscience Co. (NASDAQ:TWST)

SteelPeak Wealth LLC purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST) during the third quarter, according to its most recent filing with the SEC. The fund purchased 9,212 shares of the company’s stock, valued at approximately $416,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of TWST. Point72 Asset Management L.P. increased its holdings in Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC increased its holdings in Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after acquiring an additional 575,080 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Twist Bioscience by 4,133.1% in the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after acquiring an additional 300,891 shares during the last quarter. Farallon Capital Management LLC bought a new stake in Twist Bioscience in the 2nd quarter valued at $9,462,000. Finally, Driehaus Capital Management LLC increased its holdings in Twist Bioscience by 63.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after acquiring an additional 150,260 shares during the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research reports. Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Leerink Partners upped their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. The Goldman Sachs Group upped their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Twist Bioscience news, CFO Adam Laponis sold 856 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the sale, the chief financial officer now directly owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dennis Cho sold 709 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,300 shares of company stock valued at $1,801,822. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Down 6.5 %

Shares of TWST opened at $40.36 on Friday. The company has a 50 day moving average price of $43.77 and a 200-day moving average price of $44.94. Twist Bioscience Co. has a fifty-two week low of $15.11 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period in the previous year, the company posted ($1.01) EPS. Twist Bioscience’s revenue for the quarter was up 27.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.